The on-demand economy is large, growing and disruptive. Over the past decade or more, we’ve become accustomed to getting what we want, when we want it. Rides, groceries, crafts, liquor, lodging, obscure 80s collectibles – you name it, you can get it at the drop of an app. But organs?
Cellink, a leader in bioprinting, was built on the belief that delivering fully functioning organs on-demand can disrupt clinical testing and increase transplant success. Founded in 2016, the company is focused on developing and commercializing bioink and bioprinting technologies that enable scientists to 3D-print organs for pharmaceutical and cosmetic applications.
Cellink joined the 3DEXPERIENCE Lab program in early 2020, with the goal of optimizing its complex bioprinting process and providing a unique and intuitive 3D-design experience for its bioprinting users around the world.
With access to the 3DEXPERIENCE platform and a network of experts, the Cellink team hopes to be able to use modeling and simulation technologies to better predict and understand how living material would behave once bioprinted, anticipate problems and identify solutions before bioprinting actual structures.
“Cellink’s participation in Dassault Systemes’ 3DEXPERIENCE Lab global accelerator program is strategic to our goal of making bioprinting an intuitive process for users regardless of their level of expertise,” Cellink co-Founder and CTO Hector Martinez said in a company press release. “It also marks the official start of a promising journey led by two companies that are transforming the life sciences industry.”
. “Bioprinting offers tremendous potential to improve and extend life in all communities, from the Third World to the most advanced societies. We are pleased to partner with Cellink to accelerate maturing these disruptive technologies to serve humankind.”